**Experimental and Molecular Therapeutics—Therapeutic Mechanisms of Novel Anticancer Agents**

**Abstract #56**

*Oral presentation*

A novel B7-H6/CD3 bispecific IgG-like T cell engaging antibody for the treatment of colorectal cancer

*April 10; 17:20–17:30 (US EDT)*

*Hipp et al.*

**Experimental and Molecular Therapeutics—Biological Therapeutic Agents**

**Abstract #948**

*Poster*

Preclinical evaluation of VEGF Ang2 bispecific nanobody BI836880* in patient-derived xenograft models of nasopharyngeal carcinoma

*Wong et al.*

**Experimental and Molecular Therapeutics—Cell Death Pathways and Treatment**

**Abstract #985**

*Poster*

BI 905711* selectively induces apoptosis and anti-tumor response in TRAILR2/CDH17-expressing pancreatic cancer models

*Han et al.*

**Experimental and Molecular Therapeutics—Combination Therapies**

**Abstract #1043**

*Poster*

Enhancing cytotoxic chemotherapy effects by nintedanib** in gastric cancer preclinical models

*Awasthi et al.*

**Experimental and Molecular Therapeutics—Novel Antitumor Agents**

**Abstract #1271**

*Poster*

In *vitro* and *in vivo* characterization of BI 1823911* – a novel KRAS\(^{G12C}\) selective small molecule inhibitor

*Savarese et al.*

---

*These compounds are investigational agents and have not been approved for use. The efficacy and safety of these investigational compounds have not been established.

**Nintedanib is not approved in the US for oncology use; its safety and efficacy have not been established. Nintedanib is approved in the EU for use in combination with docetaxel in adult patients with locally advanced, metastatic, or locally recurrent NSCLC of adenocarcinoma tumor histology after first-line chemotherapy. Nintedanib is not approved in other oncology uses.

This information is for your personal use only. Copies of posters obtained through these links are for personal use only and may not be reproduced or distributed without written permission from AACR and from the authors.
Experimental and Molecular Therapeutics—Tyrosine Kinase and Phosphatase Inhibitors

Abstract #LB138
Poster
UpSwinG: real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations
Miura et al.

Abstract #1472
Poster
Novel EGFR WT sparing, HER2 selective inhibitors for the treatment of HER2 exon 20 insertion driven tumors address a clear unmet medical need
Neumüller et al.

Clinical Trials—Phase I Clinical Trials in Progress

Abstract #CT210
Poster
Trial in process: phase 1 studies of BI 1701963*, a SOS1::KRAS inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan
Hofmann et al.

Abstract #CT217
Poster
Phase I, first-in-human trial evaluating BI 1387446* (STING agonist) alone and in combination with ezabenlimab (BI 754091*; anti-PD-1) in solid tumors
Harrington et al.

Molecular and Cellular Biology / Genetics—Bcl-2 and IAP Family Proteins / Caspases

Abstract #1951
Poster
SMAC mimetics and BET inhibitors – a promising combination for solid cancer treatment?
Traexler et al.

Immunology—Immunology, Clinical Research Excluding Trials

Abstract #LB168
Poster
Blocking SIRPα on myeloid cells synergizes with radiation therapy in mouse breast cancer models
Lhuillier et al.

Meet-the-Expert

ME49
Week 2 (May 17–21)
Expanding the reach of precision oncology by drugging all KRAS mutants
Kraut et al.

*These compounds are investigational agents and have not been approved for use. The efficacy and safety of these investigational compounds have not been established.

This information is for your personal use only. Copies of posters obtained through these links are for personal use only and may not be reproduced or distributed without written permission from AACR and from the authors.

Copyright © 2021 Boehringer Ingelheim International GmbH. All rights reserved. March 2021. Vault ID: SC-CRP-08286.